Cardiomyocyte Proliferation Using Small Molecules Without Polyploidy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for heart failure, such as those caused by myocardial infarction and cardiomyopathies, are limited in their ability to regenerate functional cardiac tissue due to the low proliferation rate of cardiomyocytes, particularly in adult mice and humans, where binucleated or polyploid cardiomyocytes have reduced regenerative capacities.
Innovation Solution
The use of therapeutic agents like RepSox and its analogs, administered at concentrations between 0.1 and 10 μM, specifically targeting cardiomyocyte cultures to induce proliferation without increasing binucleation or polyploidy, and promoting the expression of VEGFR2 and ErbB2, which can be administered to subjects to treat heart damage or genetic predispositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used for heart failure, then patient survival is maintained, but cardiac tissue regeneration is limited due to low cardiomyocyte proliferation rate
Solution Approach 1:
The patent changes the physiological parameters of cardiomyocytes by administering small molecule compounds that modify cell cycle regulation, transition cardiomyocytes from a quiescent state to an active proliferation state, and alter gene expression profiles to enable cell division in adult cardiac tissue
Solution Approach 2:
The patent uses small molecule compounds as intermediaries to mediate between the administered therapy and the cardiomyocytes, where these compounds act as signaling molecules that trigger intracellular pathways leading to cell cycle re-entry and proliferation
2Productivity
If cardiomyocyte proliferation is stimulated, then cardiac tissue regeneration is improved, but binucleation and polyploidy increase reducing regenerative capacity
Solution Approach 1:
The patent applies local quality control by ensuring that proliferation is induced in specific cardiomyocyte populations while maintaining proper nuclear division, where the therapeutic agents selectively promote mitosis in mononucleated cardiomyocytes and prevent abnormal binucleation through targeted molecular mechanisms
Solution Approach 2:
The patent implements feedback control through molecular pathways that monitor and regulate the cell division process, where signaling cascades detect proper cell cycle progression and adjust proliferation rates to prevent binucleation and polyploidy while maintaining productive cardiac regeneration
3Productivity
If small molecule compounds are administered to induce proliferation, then cardiomyocyte cell cycle re-entry is achieved, but the mechanism of action requires identification and validation
Solution Approach 1:
The patent performs preliminary actions by conducting in silico screenings, in vitro assays, and in vivo studies before clinical application, where computational models predict compound mechanisms, cell culture experiments validate target engagement, and animal studies confirm efficacy and safety profiles
Solution Approach 2:
The patent replaces complex mechanical and observational methods of mechanism identification with molecular biology techniques, where gene expression analysis, protein interaction studies, and pathway activation assays substitute for traditional phenotypic screening and mechanistic investigation
Data Source
AI summary
Methods for inducing proliferation of cardiomyocytes in vitro and in vivo are disclosed.